Sangjun Yoo1, Sang Hoon Song2, Heounjeong Go3, Dalsan You1, Cheryn Song1, Jun Hyuk Hong1, Choung-Soo Kim1, Hanjong Ahn1, In Gab Jeong1. 1. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea. 2. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea. mdexodus@naver.com. 3. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Abstract
PURPOSE: Pulmonary embolism with viable tumor cells developed after surgery for renal cell carcinoma may metastasize to lung. We investigated the incidence and fate of newly developed pulmonary embolism after surgery for renal cell carcinoma with vena cava thrombus. METHODS: Among 4549 renal cell carcinoma patients treated with curative surgery at our institute from 1998 to 2015, 81 non-metastatic renal cell carcinoma patients with vena cava thrombus were included. The clinical course of pulmonary embolism and its impact on oncological outcomes were assessed. RESULTS: Postoperatively, pulmonary embolism developed in 13 patients (16.0%), who had higher level of vena cava thrombus (p = 0.004), more frequent liver mobilization (p = 0.005), and higher amount of intraoperative transfusion (p = 0.024) than patients without pulmonary embolism. The rate of lung metastasis was similar between patients with and without pulmonary embolism (30.8 vs. 35.3%, p = 1.000). In the multivariate analysis, the significant risk factors for disease recurrence were non-clear cell histology (p = 0.014) and larger primary renal tumor size (p = 0.032). Non-clear cell histology (p = 0.003) was the only significant risk factor for cancer-specific survival. Pulmonary embolism was not associated with both recurrence-free and cancer-specific survival. CONCLUSIONS: Pulmonary embolism after surgery for renal cell carcinoma with vena cava thrombus was not associated with worse oncological outcomes and can be closely followed up with anticoagulation therapy.
PURPOSE:Pulmonary embolism with viable tumor cells developed after surgery for renal cell carcinoma may metastasize to lung. We investigated the incidence and fate of newly developed pulmonary embolism after surgery for renal cell carcinoma with vena cava thrombus. METHODS: Among 4549 renal cell carcinomapatients treated with curative surgery at our institute from 1998 to 2015, 81 non-metastatic renal cell carcinomapatients with vena cava thrombus were included. The clinical course of pulmonary embolism and its impact on oncological outcomes were assessed. RESULTS: Postoperatively, pulmonary embolism developed in 13 patients (16.0%), who had higher level of vena cava thrombus (p = 0.004), more frequent liver mobilization (p = 0.005), and higher amount of intraoperative transfusion (p = 0.024) than patients without pulmonary embolism. The rate of lung metastasis was similar between patients with and without pulmonary embolism (30.8 vs. 35.3%, p = 1.000). In the multivariate analysis, the significant risk factors for disease recurrence were non-clear cell histology (p = 0.014) and larger primary renal tumor size (p = 0.032). Non-clear cell histology (p = 0.003) was the only significant risk factor for cancer-specific survival. Pulmonary embolism was not associated with both recurrence-free and cancer-specific survival. CONCLUSIONS:Pulmonary embolism after surgery for renal cell carcinoma with vena cava thrombus was not associated with worse oncological outcomes and can be closely followed up with anticoagulation therapy.
Authors: Daniel Y Woodruff; Peter Van Veldhuizen; Gregory Muehlebach; Phillip Johnson; Timothy Williamson; Jeffrey M Holzbeierlein Journal: Urol Oncol Date: 2011-04-21 Impact factor: 3.498
Authors: J C Nesbitt; E R Soltero; C P Dinney; G L Walsh; D S Schrump; D A Swanson; L L Pisters; K D Willis; J B Putnam Journal: Ann Thorac Surg Date: 1997-06 Impact factor: 4.330
Authors: Derya Tilki; Brian Hu; Hao G Nguyen; Marc A Dall'Era; Roberto Bertini; Joaquín A Carballido; Thenappan Chandrasekar; Thomas Chromecki; Gaetano Ciancio; Siamak Daneshmand; Paolo Gontero; Javier Gonzalez; Axel Haferkamp; Markus Hohenfellner; William C Huang; Theresa M Koppie; Estefania Linares; C Adam Lorentz; Philipp Mandel; Juan I Martinez-Salamanca; Viraj A Master; Rayan Matloob; James M McKiernan; Carrie M Mlynarczyk; Francesco Montorsi; Giacomo Novara; Sascha Pahernik; Juan Palou; Raj S Pruthi; Krishna Ramaswamy; Oscar Rodriguez Faba; Paul Russo; Shahrokh F Shariat; Martin Spahn; Carlo Terrone; William Thieu; Daniel Vergho; Eric M Wallen; Evanguelos Xylinas; Richard Zigeuner; John A Libertino; Christopher P Evans Journal: J Urol Date: 2014-07-22 Impact factor: 7.450
Authors: Roberto Bertini; Marco Roscigno; Massimo Freschi; Elena Strada; Diego Angiolilli; Giovanni Petralia; Rayan Matloob; Francesco Sozzi; Umberto Capitanio; Luigi Filippo Da Pozzo; Renzo Colombo; Giorgio Guazzoni; Anna Cremonini; Francesco Montorsi; Patrizio Rigatti Journal: Eur Urol Date: 2011-05-24 Impact factor: 20.096
Authors: E Jason Abel; Vitaly Margulis; Tyler M Bauman; Jose A Karam; William P Christensen; Laura-Maria Krabbe; Ahmed Haddad; Vishnukamal Golla; Christopher G Wood Journal: BJU Int Date: 2015-10-05 Impact factor: 5.588
Authors: Brian Shuch; Jeffrey C Larochelle; Thomas Onyia; Cristianna Vallera; Dan Margulis; Allan J Pantuck; Robert B Smith; Arie S Belldegrun Journal: J Urol Date: 2008-12-24 Impact factor: 7.450
Authors: Mehrad Adibi; Arun Z Thomas; Leonardo D Borregales; Surena F Matin; Christopher G Wood; Jose A Karam Journal: Urol Oncol Date: 2015-11-03 Impact factor: 3.498